Submission Guidelines

IGT x ImNO abstract submission guidelines

The IGT x ImNO Organizing Committee is inviting authors to submit abstracts for invited oral, pitch, and poster presentations.  We encourage abstract submissions related to biomedical imaging development or application in research areas such as the following:

  • Cancer (including breast, prostate)
  • Cardiac, Lung, and Musculoskeletal Imaging
  • Nuclear Imaging
  • Deep Learning/Machine Learning Methodology
  • Device, Systems, and Robotic Development
  • Image Processing & Visualization & Quantitative Biomarkers
  • Image Guided Intervention and Surgery
  • Image Guided Radiation Therapy
  • Image Guided Drug Delivery and Precision Medicine
  • Perinatal and Pediatric Imaging and Therapy
  • MR Imaging (including hyperpolarized) & Neuro Imaging
  • Optical Imaging & Ultrasound Imaging
  • E-Health, Data, and Workflow Management
  • Emerging & Interdisciplinary Technologies

Abstract Submission

All abstracts must be submitted electronically to the Conference Management Toolkit (CMT) paper submission platform no later than Friday, November 29th, 2024, 23:59 Pacific Time.

Please contact Kitty Wong (kitty.wong [at] imno.ca) for any submission-related questions.

Abstract review process

  • Abstracts will be reviewed by at least two expert reviewers. Notification of acceptance will be sent to authors on January 20, 2025
  • Presentations by trainees at the Symposium will be judged for scientific merit and organization, and the top presenters will be awarded monetary prizes. An awards ceremony will be held at the end of the Symposium.
  • Please note: Submission of an abstract constitutes permission for the conference organizers to publish the abstract in either printed or electronic format.

Mandatory formatting instructions

  • Abstract must be submitted in PDF format.
  • Abstract must not exceed one (1) letter-size (8.5×11 inches) page and must use Times New Roman 11-point font.
  • All margins must be at least 2 cm.
  • Abstract may be submitted in English or French.
  • All abstracts must be searchable.
  • Abstract must include a title section with title, list of all authors, and institutional affiliations of all authors.  Please underline the presenting author if the presenting author is not the first author.
  • Abstracts must follow the format: Introduction, Methods, Results, Conclusions.
  • Any figures and/or images must be embedded on the page.
  • By submitting an abstract, the authors agree to allow publication of the content on the symposium website and in publications and communication materials.

Abstract Instructions

  • The abstract should provide a concise and compelling summary of your research. The four Cs of abstract writing include completeness, conciseness, clarity and cohesiveness.
  • Introduction/Background (This should include the topic area, context, clinical need, disease target, description of research, novelty of research/innovation)
  • Objectives/Methods (Discuss the problem statement, hypothesis, the gap as well as the major points of your work – the design and approach)
  • Results (include significant findings of your project showing implications on how this research adds to the body of science)
  • Conclusions (include implications of your findings with evidence and data to support your conclusions)
  • Technology Transfer or Significance (Novelty, relevance, strategy, collaboration, market, IP, regulatory, etc.) * if relevant
  • Keep all elements of your abstract (pictures, tables, graphics, drawings, photos) simple. Abstract should not require extensive explanations and should include references.

Submission Checklist

  • My title is brief, descriptive, interesting, and avoids jargon.
  • I have identified the presenter by underlining their name in the author list if the presenting author is not the first author.
  • I have listed the institutional affiliations of all authors.
  • I have provided a sufficient background such that an educated but non-expert reader can understand the reason I am performing my study.
  • My hypothesis, if stated, is clear and testable. If the study truly has no hypothesis, specific objective(s) are listed in its place.
  • I have avoided jargon and uncommon acronyms, or if unavoidable, concisely defined them the first time the terms are used.
  • The sections of my abstract flow together, where the Methods address the hypothesis and/or objective(s) identified in the Introduction, the Results are the findings from the Methods I listed, and the Discussion interprets the Results and answers my hypothesis.
  • For large studies with multiple outcomes, I have selected only the most important ones that address my primary outcome(s) for inclusion in the abstract.
  • I have writtenmy abstract specifically for the IGT x ImNO Symposium audience. It is understandable by a scientifically trained but non-expert reader. It has not been copied and pasted from a specialty conference.
  • I have edited my abstract to ensure there are no spelling or grammatical errors.
  • My abstract adheres to the formatting guidelines outlined.
  • I have listed all co-authors, including my supervisors on the CMT submission form.
  • I have listed my domain conflicts and all my co-authors’ domain conflict, including my supervisor’s on the CMT submission form.

Acknowledgment:

The Microsoft CMT service was used for managing the peer-reviewing process for this conference. This service was provided for free by Microsoft and they bore all expenses, including costs for Azure cloud services as well as for software development and support.